Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats, and horses. Its lead product candidates are the intravenous, or IV, form of Zimeta (dipyrone injection), previously known as KIND-012, for the control of pyrexia (fever) in horses and Mirataz (mirtazapine transdermal ointment), formerly known as KIND-010, for management of weight loss in cats. In addition, the Company has other product candidates, including several biologics, in various stages of development.

Employee Rating

3.1More
TypePublic
HQBurlingame, US
Founded2013
Size (employees)41 (est)
Websitekindredbio.com
Kindred Biosciences was founded in 2013 and is headquartered in Burlingame, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Kindred Biosciences

Richard Chin

Richard Chin

Founder and Chief Executive Officer
Denise Bevers

Denise Bevers

Founder, President, and Chief Operating Officer
Hangjun Zhan

Hangjun Zhan

Chief Scientific Officer
Wendy Wee

Wendy Wee

CFO
Karen Greenwood

Karen Greenwood

Vice President of Project Management
Katja Buhrer

Katja Buhrer

Vice President of Corporate Development and Investor Relations
Show more

Kindred Biosciences Office Locations

Kindred Biosciences has an office in Burlingame
Burlingame, (HQ)
200 1555 Old Bayshore Hwy
Show all (1)
Report incorrect company information

Kindred Biosciences Financials and Metrics

Kindred Biosciences Revenue

USD

Net income (Q3, 2018)

(13.0m)

EBIT (Q3, 2018)

(13.6m)

Market capitalization (4-Dec-2018)

425.6m

Closing stock price (4-Dec-2018)

12.6

Cash (30-Sep-2018)

70.0m
Kindred Biosciences's current market capitalization is $425.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

7.9m8.3m14.0m

R&D expense

19.4m13.9m17.7m

Operating expense total

27.3m22.8m31.7m

EBIT

(27.3m)(22.8m)(31.7m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

1.9m2.1m2.0m1.9m2.0m2.8m3.1m3.3m4.9m5.8m6.6m

R&D expense

5.0m5.0m3.4m3.2m3.8m3.8m3.9m4.9m5.3m5.8m7.5m

Operating expense total

6.9m7.1m6.1m5.0m5.8m6.6m6.9m8.1m10.2m11.6m14.2m

EBIT

(6.9m)(7.1m)(6.1m)(5.0m)(5.8m)(6.6m)(6.9m)(8.1m)(10.2m)(11.6m)(13.6m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.0m20.0m6.7m34.8m

Inventories

1.9m1.8m

Current Assets

101.5m73.8m58.0m81.8m

PP&E

394.0k1.2m2.4m7.5m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

14.8m4.5m9.6m16.0m13.3m19.9m36.9m43.6m44.5m85.4m70.0m

Accounts Receivable

2.1m492.0k242.0k

Inventories

2.5m

Current Assets

90.2m84.0m69.4m62.1m61.4m68.4m75.3m87.2m72.2m111.5m95.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(120.0k)(27.1m)(5.8m)(30.9m)

Depreciation and Amortization

146.0k155.0k475.0k

Inventories

(14.1m)16.0m(37.9m)

Accounts Payable

6.0k30.0k(710.0k)1.3m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(6.9m)(7.1m)(6.1m)(11.0m)(16.7m)(6.5m)(13.3m)(21.1m)(10.0m)(21.2m)(34.2m)

Depreciation and Amortization

75.0k115.0k46.0k162.0k295.0k144.0k324.0k527.0k

Inventories

(2.5m)

Accounts Payable

347.0k1.1m285.0k567.0k(221.0k)141.0k726.0k515.0k340.0k(1.2m)(2.5m)(60.0k)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Kindred Biosciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Kindred Biosciences News and Updates

Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President

SAN FRANCISCO, Oct. 23, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio, has been elected...

Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

SAN FRANCISCO, Sept. 17, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Cantor Global Healthcare Conference on October 1 and the Ladenburg Thalmann 2018...

Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

SAN FRANCISCO, Aug. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place September 4th, the CL King 16th Annual...

Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference

SAN FRANCISCO, Aug. 21, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4th in New York...

Kindred Biosciences Announces Second Quarter 2018 Financial Results

SAN FRANCISCO, Aug. 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2018 and provided updates on its...
Report incorrect company information

Kindred Biosciences Blogs

Kindred Biosciences Announces Third Quarter 2018 Financial Results

San Francisco, CA (November 7, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its programs. For the…

Event: Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

Tuesday, October 30, 2018 Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID:7047158 For more information about this event, please see the press release.

Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

Statistically significant reduction in pruritus versus placebo was achieved across all dose groups. Canine atopic dermatitis is a large and growing market, and KindredBio has a broad portfolio of biologics in development to treat this condition. San Francisco, CA (October 30, 2018) — Kindred Bioscie…

Event: Kindred Biosciences to Announce Third Quarter 2018 Financial Results

Wednesday, November 7, 2018 Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID: 5790907 For more information about this event, please see the press release.

Kindred Biosciences to Announce Third Quarter 2018 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, November 7, 2018 San Francisco, CA (October 24, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, …

Event: Kindred Biosciences to Present at Ladenburg Thalmann 2018 Healthcare Conference

Tuesday, October 2, 2018 Location: Sofitel New York, Track 4 – St. Germain III Presentation time: 3:00 – 3:25 PM ET Company Attendee: Denise Bevers, Co-Founder and Chief Operating Officer Webcast URL: Click here For more information about this event, please see the press release.
Show more

Kindred Biosciences Company Life and Culture

Report incorrect company information

Kindred Biosciences Frequently Asked Questions

  • When was Kindred Biosciences founded?

    Kindred Biosciences was founded in 2013.

  • Who are Kindred Biosciences key executives?

    Kindred Biosciences's key executives are Richard Chin, Denise Bevers and Hangjun Zhan.

  • How many employees does Kindred Biosciences have?

    Kindred Biosciences has 41 employees.

  • Who are Kindred Biosciences competitors?

    Competitors of Kindred Biosciences include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Pfizer.

  • Where is Kindred Biosciences headquarters?

    Kindred Biosciences headquarters is located at 200 1555 Old Bayshore Hwy, Burlingame.

  • Where are Kindred Biosciences offices?

    Kindred Biosciences has an office in Burlingame.

  • How many offices does Kindred Biosciences have?

    Kindred Biosciences has 1 office.